U.S. officials say small pharmaceutical companies have 180 days to avoid higher tariffs, and companies that move manufacturing back to the U.S. and sign Most Favored Nation (MFN) drug pricing agreements with the U.S. Department of Health and Human Services will be exempt from drug tariffs.